Roche walks away, leaving HOOKIPA to rally behind lead asset
29 Jan 2024
ImmunotherapyLicense out/inClinical Trial Failure
Roche is ending its interest in HOOKIPA Pharma’s experimental arenaviral immunotherapy for KRAS-mutated cancers, forcing the latter to regroup behind its lead pipeline candidate and make workforce cuts. HOOKIPA’s shares tumbled on Monday around 11% on the news.
HOOKIPA had been eligible to receive over $900 million as part of the agreement with Roche for HB-700, which is yet to enter clinical development. HOOKIPA indicated that it “has met all go-forward criteria” under the deal, without giving further details on Roche’s decision. The drugmaker noted it will seek a new partner for the programme and expects to submit an IND before the end of March.
Meanwhile, HOOKIPA said that it will pause early-stage development of HB-300 in prostate cancer and scale back on the majority of preclinical research activities. The moves are designed to free-up resources to put behind development of HB-200 in first- and second-line HPV16+ head and neck squamous cell carcinoma (HNSCC), as well as two infectious disease programmes partnered with Gilead Sciences.
HOOKIPA will reduce its workforce by around 30%.
More to follow.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.